Tyrosinase inhibitors are the first-line topical approach to acquired hyperpigmentation, including melasma and post-inflammatory hyperpigmentation. Five agents dominate clinical use in UK practice: hydroquinone, azelaic acid, kojic acid, arbutin, and niacinamide. Each works through a distinct mechanism, carries a different evidence base, and suits different patient presentations. Understanding the differences is what separates a protocol that holds from one that flatlines at eight weeks.
What Tyrosinase Inhibitors Actually Do
Melanin is produced through a multistep enzymatic process inside melanocytes. Tyrosinase catalyses the rate-limiting steps: the hydroxylation of tyrosine to L-DOPA, and the oxidation of L-DOPA to dopaquinone. Inhibit that enzyme and you reduce how much melanin the cell can produce.
Not all five agents act at that same point. Niacinamide, for instance, does not inhibit tyrosinase at all. It intervenes downstream, blocking the transfer of melanosomes from melanocytes to adjacent keratinocytes. This distinction matters clinically: combining a tyrosinase inhibitor with niacinamide targets two separate steps in the pigment pathway. The combination has a stronger evidence base than either agent alone, and it is the approach the literature increasingly supports.
Hydroquinone: The Reference Standard
Hydroquinone has been in clinical use since the 1960s and remains the agent against which all others are measured. It works through competitive inhibition of tyrosinase and, at higher concentrations, is directly cytotoxic to hyperactive melanocytes. That dual mechanism gives it reliable, rapid efficacy in melasma and PIH where other agents have stalled.
Standard prescribing concentrations in UK clinical practice are 2 to 4%. Concentrations above 4% require careful patient selection and close monitoring. Two clinical concerns frame long-term use: paradoxical hyperpigmentation (ochronosis) with prolonged high-concentration application, and rebound pigmentation when UV protection lapses.
Hydroquinone is a prescription-only medicine in the UK. Aesthetic practitioners who prescribe it must hold the appropriate qualification and indemnity. The JCCP includes prescribing scope within its practitioner competency framework, and it is worth confirming that any prescriber referral or independent prescribing arrangement is documented in the clinical record.
Azelaic Acid: The MHRA-Sanctioned First-Line Option
Azelaic acid at 15 to 20% is prescription-only; 10% is available OTC. It is the agent most commonly recommended at first line for melasma in UK primary care and dermatology, and for good reason. Unlike hydroquinone, azelaic acid inhibits tyrosinase selectively in abnormal melanocytes. It has a preferential effect on hyperpigmented tissue and a comparatively low impact on normally pigmented skin. That selectivity matters: it reduces the risk of unintended lightening around the treatment area, particularly relevant in Fitzpatrick III to VI.
A systematic review and meta-analysis examining azelaic acid versus hydroquinone across randomised controlled trials found the two agents non-inferior in melasma severity scores, with azelaic acid demonstrating a more favourable adverse effect profile. For practitioners advising patients on topical protocols, this makes azelaic acid a strong default, particularly for those with darker skin tones or sensitivity histories.
Azelaic acid also carries established anti-inflammatory and antibacterial properties. In post-inflammatory hyperpigmentation secondary to acne or rosacea, this secondary mechanism is directly relevant: the agent addresses both the residual pigment and the inflammatory microenvironment that generated it.
Kojic Acid and Arbutin: Established but Constrained
Kojic acid, derived from fungal fermentation, chelates the copper ions at tyrosinase's active site. Multiple controlled studies show statistically significant improvements in melasma compared to placebo, and it is frequently incorporated into combination formulations alongside hydroquinone or glycolic acid. The limitation is formulation stability: kojic acid oxidises readily, losing bioavailability before it reaches target tissue. Encapsulated forms improve this, but the controlled trial evidence for those specific preparations is thinner.
Arbutin is a glycoside that hydrolyses to hydroquinone in the skin, providing the same tyrosinase-inhibiting effect through a slower, more tolerated release profile. Alpha-arbutin carries stronger inhibitory activity than beta-arbutin at equivalent concentrations. The controlled evidence across clinical trials is positive, but largely in combination protocols, which makes it difficult to isolate arbutin's individual contribution.
Both agents are available without prescription in cosmeceutical formulations. Practitioners will encounter them in patients' existing routines. They are useful adjuncts in a layered protocol. They are unlikely to carry a treatment plan on their own.
Niacinamide: A Downstream Mechanism
Niacinamide (vitamin B3) does not inhibit tyrosinase. It acts at a different point entirely: the transfer of melanosomes from melanocytes to the surrounding keratinocytes, the final step by which pigment moves into the visible skin layers.
Two randomised controlled trials have demonstrated clinically meaningful reductions in facial hyperpigmentation with 4 to 5% niacinamide versus vehicle, with a 35 to 68% reduction in melanosome transfer across studies. It is well tolerated across all Fitzpatrick types, widely available in cosmeceutical concentrations, and carries an anti-inflammatory secondary profile useful in mixed PIH presentations.
The Journal of the American Academy of Dermatology's comprehensive review of hyperpigmentation management supports niacinamide's inclusion in combination protocols as a complementary active. Pairing a tyrosinase inhibitor with niacinamide targets the pigment pathway at two independent points: one upstream at melanin synthesis, one downstream at the point of transfer. The logic is mechanistically sound and the clinical data supports the combination.
Selecting and Sequencing Agents in Practice
Choosing between these agents depends on the hyperpigmentation subtype, Fitzpatrick type, barrier condition, and patient sensitivity profile.
Melasma (hormonally driven): Azelaic acid as first line in most cases. Hydroquinone where azelaic acid has not achieved adequate response after a full trial period of twelve weeks. Niacinamide throughout as a complementary active regardless of primary agent. Kojic acid in formulated combinations where additional inhibition is wanted.
Post-inflammatory hyperpigmentation: Address the trigger first. Azelaic acid is well positioned for PIH secondary to acne or rosacea. Graduated retinoid introduction alongside to support cell turnover. Niacinamide at all skin types and Fitzpatrick stages. Be conservative with hydroquinone in Fitzpatrick IV to VI until the inflammatory trigger is stable.
Solar lentigines: Lower concentrations of the same tyrosinase inhibitors are often sufficient. Photoprotection remains the dominant variable. Without consistent SPF 50 on a daily basis, any topical active is managing a tap left running.
Sequencing within a topical protocol also matters. Chemical exfoliation, including well-timed peels or AHA use, improves penetration of depigmenting actives, particularly in Fitzpatrick III to VI skin where barrier thickness can limit absorption. That said, barrier tolerance must be assessed before layering multiple actives: irritation-driven inflammation is itself a PIH trigger, and undoing that takes longer than the initial improvement took to achieve.
The free pigmentation quiz gives practitioners a structured starting-point assessment of pigment type and likely triggers before advising on a protocol.
If you want the full clinical decision framework for hyperpigmentation, from presentation assessment through active selection and patient communication, Hyperpigmentation Decoded, The Mini covers it across three free lessons. It is built on the same evidence-led framework used at Bernadette's clinic, where hyperpigmentation is among the presentations seen most weeks of the year. The full Hyperpigmentation Decoded programme takes the layered protocol further, including the device and chemical peel options and when they add to rather than replace the topical foundation.
FAQ
Do tyrosinase inhibitors work on all types of hyperpigmentation?
They are most effective in conditions driven by excess melanin synthesis: melasma, some post-inflammatory hyperpigmentation, and solar lentigines. Vascular pigmentation, post-inflammatory erythema, and conditions where dermal rather than epidermal melanin predominates are less responsive to topical actives alone and may need a different treatment strategy.
Is hydroquinone safe for long-term use?
Short-term cyclical use at 2 to 4% is generally well tolerated. Prolonged, uninterrupted use at higher concentrations carries a risk of ochronosis (paradoxical darkening) in some patients. Standard clinical practice involves defined treatment cycles with breaks, always alongside daily SPF 50.
Can these agents be used safely on darker skin tones?
Azelaic acid, niacinamide, and arbutin have well-established tolerability across Fitzpatrick III to VI. Higher concentrations of hydroquinone require closer monitoring in darker skin types due to the risk of uneven pigment change. Kojic acid at higher doses can provoke contact sensitivity. Barrier condition and Fitzpatrick assessment should precede any protocol, and the first cycle should be conservative.
Does niacinamide lighten normal skin?
No. Niacinamide reduces melanosome transfer specifically, it does not bleach or permanently lighten normally pigmented skin. This targeted mechanism makes it suitable as a maintenance active once a hyperpigmentation episode has resolved, without risk of depigmenting surrounding areas.
How long before topical tyrosinase inhibitors produce visible results?
Typically eight to twelve weeks for initial clinical change, with maximum benefit at sixteen to twenty-four weeks depending on the agent, concentration, and adherence to photoprotection. Results also depend on whether the causative trigger, whether hormonal, inflammatory, or UV-driven, has been identified and addressed. Without that, any topical active is working against the clock.